Multiplatform molecular profiling: Observational study to determine the effect of treatment selection in advanced or refractory metastatic solid tumors.

person Faraz A. Khan American Hospital Dubai, Dubai, United Arab Emirates info_outline Faraz A. Khan, Maroun EL Khoury, Thalia Safar, Mona Tareen, Kadriya Sayed

Authors person Faraz A. Khan American Hospital Dubai, Dubai, United Arab Emirates info_outline Faraz A. Khan, Maroun EL Khoury, Thalia Safar, Mona Tareen, Kadriya Sayed Organizations American Hospital Dubai, Dubai, United Arab Emirates, Georgetown University, Washington DC, DC, American Hospital, Dubai, United Arab Emirates Abstract Disclosures Research Funding Other Background: To assess the clinical benefit of treatment in advanced and refractory solid tumors utilizing evidence-guided molecular profiling (MP) of tumors in routine clinical practice. Methods: This retrospective observational study was conducted on patients with advanced or refractory metastatic solid tumors, whose tumor biopsy samples were referred for profiling using a multi-platform tumor profiling service (Caris Molecular Intelligence) between January 2014 and April 2017. Specific testing was performed per physician’s request and included a combination of next-generation sequencing (NGS), protein expression (IHC), gene amplification (CISH or FISH), and/or RNA fusion analysis. Results: Data of twenty five patients with solid tumors was analyzed (median age of 58 years, range 25-82 years). Patients had received a median of 2 prior lines of therapy (range 0-6). In evaluable patients, 1 (4%) patient had a complete response, 10 (46%) patients had a partial response, 5 (23%) had stable disease and 6 (27%) had progressive disease, giving a disease control rate of 73%. The majority of patients received chemotherapy (CT) alone (13; 56%). Five patients received CT combined with targeted therapy (TT), 2 received TT alone, 2 received TT combined with hormone therapy (HT), 2 have received immunotherapy and 1 received HT alone. Two patients were not evaluable for response. In responding patients, median duration of response was 7 months (3-18 months). Conclusions: The result of this study show that treatment based on Broad tumor profiling in a select group of advanced and refractory solid tumors was associated with a high disease control rate.